Side effects of Avandia - Rosiglitazone is the active ingredient in the controversial type 2 diabetes medicine Avandia and has been linked to an increased risk of serious cardiovascular problems such as stroke, heart failure, and death. A common alternative treatment is pioglitazone, the active ingredient in a diabetes medicine called Actos. In a nationwide retrospective observational study of 227,571 Medicare beneficiaries aged 65 years or older, it was found that 2,593 of the 67,593 patients using rosiglitazone and 5,386 of the 159,978 using pioglitazone had serious cardiovascular problems. The data is summarized in the contingency table below. Cardiovascular problems Yes No Total Rosiglitazone 2,593 65,000 67,593 Pioglitazone 5,386 154,592 159,978 Total 7,979 219,592 227,571 1. What proportion of all patients had cardiovascular problems? Round your answer to four decimal places. 0.0351 2. What is the difference in proportion of patients with cardiovascular problems between the Rosiglitazone group and the Pioglitazone group? Round your answer to four decimal places. 0.0047 3. If the type of treatment and having cardiovascular problems were independent (null hypothesis), what would we expect the difference in proportion of patients with cardiovascular problems between the Rosiglitazone group and the Pioglitazone group to be? Answer as a whole number.
Side effects of Avandia - Rosiglitazone is the active ingredient in the controversial type 2 diabetes medicine Avandia and has been linked to an increased risk of serious cardiovascular problems such as stroke, heart failure, and death. A common alternative treatment is pioglitazone, the active ingredient in a diabetes medicine called Actos. In a nationwide retrospective observational study of 227,571 Medicare beneficiaries aged 65 years or older, it was found that 2,593 of the 67,593 patients using rosiglitazone and 5,386 of the 159,978 using pioglitazone had serious cardiovascular problems. The data is summarized in the contingency table below. Cardiovascular problems Yes No Total Rosiglitazone 2,593 65,000 67,593 Pioglitazone 5,386 154,592 159,978 Total 7,979 219,592 227,571 1. What proportion of all patients had cardiovascular problems? Round your answer to four decimal places. 0.0351 2. What is the difference in proportion of patients with cardiovascular problems between the Rosiglitazone group and the Pioglitazone group? Round your answer to four decimal places. 0.0047 3. If the type of treatment and having cardiovascular problems were independent (null hypothesis), what would we expect the difference in proportion of patients with cardiovascular problems between the Rosiglitazone group and the Pioglitazone group to be? Answer as a whole number.
MATLAB: An Introduction with Applications
6th Edition
ISBN:9781119256830
Author:Amos Gilat
Publisher:Amos Gilat
Chapter1: Starting With Matlab
Section: Chapter Questions
Problem 1P
Related questions
Question
I need help with 3 plz
Transcribed Image Text:Side effects of Avandia - Rosiglitazone is the active ingredient in the controversial type 2 diabetes medicine Avandia and has been linked to an
increased risk of serious cardiovascular problems such as stroke, heart failure, and death. A common alternative treatment is pioglitazone, the active
ingredient in a diabetes medicine called Actos. In a nationwide retrospective observational study of 227,571 Medicare beneficiaries aged 65 years or
older, it was found that 2,593 of the 67,593 patients using rosiglitazone and 5,386 of the 159,978 using pioglitazone had serious cardiovascular
problems. The data is summarized in the contingency table below.
Cardiovascular problems
Yes
No
Total
Rosiglitazone
2,593
65,000
67,593
Pioglitazone
5,386
154,592
159,978
Total
7,979
219,592
227,571
1. What proportion of all patients had cardiovascular problems? Round your answer to four decimal places. 0.0351
2. What is the difference in proportion of patients with cardiovascular problems between the Rosiglitazone group and the Pioglitazone group? Round
your answer to four decimal places. 0.0047
3. If the type of treatment and having cardiovascular problems were independent (null hypothesis), what would we expect the difference in proportion
of patients with cardiovascular problems between the Rosiglitazone group and the Pioglitazone group to be? Answer as a whole number.
Expert Solution
This question has been solved!
Explore an expertly crafted, step-by-step solution for a thorough understanding of key concepts.
This is a popular solution!
Trending now
This is a popular solution!
Step by step
Solved in 2 steps with 2 images
Knowledge Booster
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, statistics and related others by exploring similar questions and additional content below.Recommended textbooks for you
MATLAB: An Introduction with Applications
Statistics
ISBN:
9781119256830
Author:
Amos Gilat
Publisher:
John Wiley & Sons Inc
Probability and Statistics for Engineering and th…
Statistics
ISBN:
9781305251809
Author:
Jay L. Devore
Publisher:
Cengage Learning
Statistics for The Behavioral Sciences (MindTap C…
Statistics
ISBN:
9781305504912
Author:
Frederick J Gravetter, Larry B. Wallnau
Publisher:
Cengage Learning
MATLAB: An Introduction with Applications
Statistics
ISBN:
9781119256830
Author:
Amos Gilat
Publisher:
John Wiley & Sons Inc
Probability and Statistics for Engineering and th…
Statistics
ISBN:
9781305251809
Author:
Jay L. Devore
Publisher:
Cengage Learning
Statistics for The Behavioral Sciences (MindTap C…
Statistics
ISBN:
9781305504912
Author:
Frederick J Gravetter, Larry B. Wallnau
Publisher:
Cengage Learning
Elementary Statistics: Picturing the World (7th E…
Statistics
ISBN:
9780134683416
Author:
Ron Larson, Betsy Farber
Publisher:
PEARSON
The Basic Practice of Statistics
Statistics
ISBN:
9781319042578
Author:
David S. Moore, William I. Notz, Michael A. Fligner
Publisher:
W. H. Freeman
Introduction to the Practice of Statistics
Statistics
ISBN:
9781319013387
Author:
David S. Moore, George P. McCabe, Bruce A. Craig
Publisher:
W. H. Freeman